Schechter Investment Advisors LLC Acquires 2,884 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Schechter Investment Advisors LLC increased its position in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 2.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 119,668 shares of the company’s stock after acquiring an additional 2,884 shares during the period. Schechter Investment Advisors LLC’s holdings in Takeda Pharmaceutical were worth $1,584,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Public Employees Retirement System of Ohio bought a new stake in shares of Takeda Pharmaceutical in the third quarter worth $601,000. Verition Fund Management LLC purchased a new position in Takeda Pharmaceutical during the third quarter valued at $1,533,000. QRG Capital Management Inc. lifted its position in Takeda Pharmaceutical by 16.8% during the fourth quarter. QRG Capital Management Inc. now owns 329,644 shares of the company’s stock valued at $4,364,000 after purchasing an additional 47,490 shares in the last quarter. HighTower Advisors LLC lifted its position in Takeda Pharmaceutical by 199.5% during the third quarter. HighTower Advisors LLC now owns 122,587 shares of the company’s stock valued at $1,744,000 after purchasing an additional 81,653 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in Takeda Pharmaceutical during the third quarter valued at $957,000. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

NYSE TAK opened at $14.84 on Tuesday. The company has a market capitalization of $47.22 billion, a PE ratio of 37.10, a price-to-earnings-growth ratio of 0.24 and a beta of 0.51. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. The business’s fifty day moving average is $13.44 and its 200 day moving average is $13.89. Takeda Pharmaceutical Company Limited has a fifty-two week low of $12.57 and a fifty-two week high of $15.08.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Sell-side analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.